TLB Business Summary

Tien Liang BioTech Co., Ltd. (TLB) operates a diversified pharmaceutical business model focused on the manufacture, wholesale, and retail of both traditional and modern medical solutions. The company generates revenue through transaction-based sales of its proprietary formulations across three primary segments: Chinese Herbal Medicine, which includes treatments for rheumatism and organ deficiencies; Western Medicine, comprising generic capsules, tablets, and topical ointments; and Healthcare and Cosmetics, featuring health foods, skincare, and personal care products. TLB utilizes a multi-channel distribution strategy encompassing both physical retail networks and e-commerce platforms. Within the Taiwanese market, TLB competes directly with firms such as Anya Biopharm (7776.TWO), Advagene Biopharma (6709.TWO), InnoPharmax (4172.TWO), and Chi Sheng Pharma & Biotech (4111.TWO), maintaining a specialized niche by bridging the gap between traditional herbal remedies and standardized generic pharmaceuticals. The company is currently led by Chairman Zhan Han Shan (Han Shan Zhan), who serves as the representative head of the board, and Chief Executive Officer Hsi Tsung Shen, who was appointed to the role in May 2024 to spearhead the firm's modern strategic expansion. The executive team is supported by Finance Manager and Accounting Supervisor Junxiong Guo, who oversees the company's fiscal health and reporting. Founded in 1971 and headquartered in New Taipei City, TLB's leadership leverages over five decades of institutional knowledge in the Taiwanese healthcare sector. The board of directors, which includes independent members such as Mei Ling Jiang, provides oversight for the company's research and development initiatives and its ongoing transition toward a more digitally integrated sales model.